MétaCan
Menu
Back to cohort
Record W4405043558 · doi:10.1182/blood-2024-194886

Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC

2024· article· en· W4405043558 on OpenAlexaff
Nihar Desai, Tommy Alfaro Moya, Igor Novitzky‐Basso, Ivan Pašić, Wilson Lam, Fotios V. Michelis, Armin Gerbitz, Dennis Dong Hwan Kim, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Arjun Law

Bibliographic record

VenueBlood · 2024
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsUniversity of TorontoUniversity Health NetworkPrincess Margaret Cancer Centre
Fundersnot available
KeywordsTransplantationStem cellABO blood group systemHematopoietic stem cell transplantationImmunologyHaematopoiesisMedicineBiologyInternal medicineGenetics

Abstract

fetched live from OpenAlex

Introduction: ABO blood group incompatibility is not a barrier to allogeneic hematopoietic stem cell transplantation (allo-HCT). This may be observed in about half of all allo-HCT with differing degrees of mismatch (mm) i.e. major, minor, or bidirectional. Despite numerous factors affecting allo-HCT outcomes, the impact of donor-recipient ABO mm is not well characterized. Methods: To investigate the association between ABO mm and allo-HCT outcomes in patients receiving post-transplant cyclophosphamide (PTCy) graft versus host disease (GVHD) prophylaxis, we retrospectively analyzed patients undergoing allo-HCT between October 2015 & December 2023. Cumulative incidences were analyzed using competing risk models. Multivariable Cox regression analysis (MVA) assessed risk factors for overall survival (OS) and GVHD-free/relapse-free survival (GRFS). Fine-gray regression was used for non-relapse mortality (NRM), cumulative incidence of relapse (CIR), GVHD, and primary graft failure (PGF). A p-value of <0.05 was considered statistically significant, and analyses were conducted using EZR (version 1.62). Results: A total of 1089 patients [median age 59 years (IQR 47-66); male, 57%] underwent allo-HCT. The predominant indication for allo-HCT was acute myeloid leukemia (n=543, 49%). Most received a graft from a matched unrelated donor (n=540, 49.6%). The KPS was >80% in 900 (82.6%) patients and the HCT-CI score was <3 in 80.3%. The conditioning regimen was reduced intensity (RIC) in 801 (73.5%). Peripheral blood grafts were used in 98% of the cases, the median CD34+ cell dose was 7.4x106/kg (IQR 5.6-8.4). Most patients received fresh grafts (n=847, 77.8%). ABO-matched grafts were used in 646 patients (59%), 212 (20%) had a minor mm, 175 (16%) had a major mm, and 56 (5%) had bidirectional mm. The 2-year OS for recipients of a major ABO-mm graft was 57.7% (49.7-64.9) vs 64.9% (61.4-68.2) for ABO-matched grafts [HR 1.32 (1.1-1.6), p=0.003]. The incidence of PGF at D+100 was 4.6% (2.2-8.5) for major mm grafts and 1.9% (1.1-2.9) for ABO-matched grafts [HR 2.88 (1.2 - 6.7); p=0.01]. Platelet engraftment occurred at a median of 23 days (20-26) in patients with major mm and 20 days (19-21) for ABO-matched grafts (p=0.005). There was no significant difference in the rate of neutrophil engraftment. By D+30, 95.4% (90.4-97.8) of major mm recipients had engrafted compared to 95.1% (93.4-96.3) of ABO-matched recipients. The median day of neutrophil engraftment was day 18 (17-19) for both groups (p=0.93). The D+100, grade III-IV aGVHD was 6.1% (3.1-10.5) and 6.6% (5-8.5), for major mm and ABO-matched grafts, respectively (p=0.71). At 2-years, moderate-severe cGVHD was 19% (13.1-25.7) vs 17.7% (15-20.6) for major mm and ABO-matched grafts, respectively (p=0.79). There was no significant difference in NRM at 1 year between patients with major mm [18.8% (13.3-25.1)] and those with ABO-matched grafts [16.5% (14.1-19.1), p=0.07]. The CIR at 2-years was comparable between the two groups [22.5% (16.4-29.2) vs 23.1% (20.2-26.1); p=0.94]. The GRFS at 12 and 24 months was 41.4% (33 - 48) and 35.7% (28 - 43) respectively in the ABO mm group, compared to 47.8% (44 - 51) and 43.8% (40 - 47) in those with ABO-matched grafts (p=0.16). MVA identified major ABO mm, recipient age, HLA-mismatch, and a diagnosis of myelofibrosis as predictors for PGF and delayed platelet engraftment. Recipient age, HLA-mismatch, use of cryopreserved grafts, KPS <90%, HCTCI>3, and high-very high DRI were predictors for OS. In the RIC subgroup (n=801, 73.6%), the 2-year OS for major mm grafts was 54% (44.9-62.3) vs 61.3% (57.2-65.1) for ABO-matched grafts [HR 1.32 (1.1-1.7), p=0.04]. The incidence of PGF was 5.2% (2.3-9.9) for major mm grafts vs 2.4% (1.4-3.8) for ABO-matched grafts [HR 2.49 (1.1 - 6.1); p=0.04]. In patients with major mm grafts, platelet engraftment occurred at a median of 23 days (21-26) vs 21 days (20-22) for ABO-matched grafts (p=0.01). Major ABO mm was predictive of delayed platelet engraftment on MVA. The effects of ABO mm on OS, PGF, and platelet engraftment were not demonstrated in patients receiving myeloablative conditioning. Conclusion: Major ABO mismatch is associated with higher PGF rates, and delayed platelet engraftment, particularly in patients receiving RIC and PTCy-based GVHD prophylaxis. However, ABO mismatch does not significantly affect OS, NRM. CIR, neutrophil engraftment, or the incidence of GVHD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.238
Teacher spread0.227 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBloodSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207